N
NuCana plc (NCNA)
NCM – Real Time Price. Currency in USD
1.86
-0.11 (-5.58%)
At close: May 12, 2026, 4:00 PM EDT
1.90
+0.04 (2.15%)
Pre-market: May 13, 2026, 5:27 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.86
-0.11 (-5.58%)
At close: May 12, 2026, 4:00 PM EDT
1.90
+0.04 (2.15%)
Pre-market: May 13, 2026, 5:27 AM EDT
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
| Name | Position |
|---|---|
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer |
| Dr. Stuart Grant | Senior Vice President of Regulatory Affairs |
| Mr. Gordon Kennovin | Senior VP of CMC & Development |
| Mr. Hugh Stephen Griffith | Founder, CEO & Executive Director |
| Mr. Ian Webster | Interim Chief Financial Officer |
| Mr. Martin Alexander Quinn | Company Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | d118567d6k.htm |
| 2026-03-19 | S-8 | d19997ds8.htm |
| 2026-03-19 | 20-F | ncna-20251231.htm |
| 2026-01-06 | 6-K | d19790d6k.htm |
| 2025-12-17 | 6-K | d46511d6k.htm |
| 2025-12-10 | 6-K | d23141d6k.htm |
| 2025-11-13 | 6-K | d936510d6k.htm |
| 2025-11-05 | 6-K | d87120d6k.htm |
| 2025-10-20 | 6-K | d917681d6k.htm |
| 2025-10-14 | 6-K | d88344d6k.htm |
| Ms. Theresa Bruce | Chief Operating Officer |
| Prof. David Harrison | Head of Translational Medicine & Studies |